Cytosorbents Corp (CTSO)
Health Services • Health Care
July 20, 2026 CytoSorbents Corporation to Announce Second Quarter 2026 Results CytoSorbents Corporation is set to announce its Q2 2026 financial results on August 6, followed by a live conference call. The company specializes in blood purification technologies, with a focus on critical care and cardiac surgery. Investors await insights on business progress and regulatory efforts.
April 30, 2026 CytoSorbents Corporation Set to Reveal Q1 2026 Financial Results CytoSorbents Corporation is set to reveal its financial results for Q1 2026 on May 13. This report will shed light on the company's performance and future strategies in blood purification technologies. Key developments, including regulatory updates, are anticipated to be discussed during the live conference call.
March 30, 2026 Cytosorbents Corp Reports 2025 Annual Results: A Year of Challenges and Growth Cytosorbents Corp's 2025 annual report highlights a 4.1% revenue increase to $37.1 million, despite challenges in Germany and rising costs. The company is focused on innovation and operational efficiency as it aims for future growth and profitability.
March 25, 2026 CytoSorbents Reports Financial Results and Key Developments for 2025 CytoSorbents Corporation reported a 4% revenue increase in 2025, driven by international sales. The company highlights clinical advancements and a focus on reaching cash flow breakeven by 2026, despite challenges in the domestic market.
March 19, 2026 CytoSorbents Announces Exciting Innovations at ISICEM 2026 At ISICEM 2026, CytoSorbents introduced the HotSwap™ system for rapid blood purification device exchanges, renewed its partnership with Aferetica, and presented new clinical data supporting CytoSorb therapy's efficacy in critical care, promising to improve patient outcomes significantly.
November 13, 2025 Cytosorbents Corp Reports Strong Q3 2025 Financials Amid Strategic Changes Cytosorbents Corp showcased a 10.1% revenue growth in Q3 2025, achieving approximately $9.5 million in total revenue. Despite facing operational challenges, the company is focusing on strategic changes, including a workforce reduction, to enhance financial stability and address regulatory hurdles.
August 07, 2025 Cytosorbents Corp. Reports Q2 2025 Financial Results: A Mixed Bag Amid Regulatory Challenges Cytosorbents Corp. reports mixed Q2 2025 results, with an 8.8% revenue increase to $9.6 million and a net income turnaround to $1.94 million. Regulatory challenges persist, particularly with the DrugSorb-ATR device, while favorable currency impacts aid financial performance.
May 14, 2025 Cytosorbents Corp Reports Q1 2025 Results: A Mixed Bag of Progress and Challenges Cytosorbents Corp reported mixed Q1 2025 results, with revenues declining slightly but improved financial metrics. The company faces regulatory challenges while maintaining operational efficiencies and innovating in blood purification technologies.
March 31, 2025 Cytosorbents Corp Reports Strong Growth in 2024 Annual Report Cytosorbents Corp's 2024 annual report reveals a 15% rise in revenue, driven by product advancements and strategic initiatives. The company continues to innovate in blood purification technologies while managing operational challenges and legal issues.
March 06, 2025 SWOT Analysis of Cytosorbents Corp in 2025 This SWOT analysis details Cytosorbents Corp's strengths in innovative blood purification technologies and strategic partnerships, while also addressing weaknesses like financial instability. Opportunities for growth in emerging markets and the global blood purification sector are highlighted alongside potential threats from competition and regulatory challenges.
March 04, 2025 CytoSorbents Postpones Earnings Release Amid Leadership Transition CytoSorbents Corporation has postponed its earnings call to March 25, 2025, following the unexpected passing of VP James E. Cason, Jr. The company provided preliminary financial expectations while navigating this leadership transition.
February 26, 2025 CytoSorbents Corporation Set to Reveal Q4 and Full Year 2024 Financial Results CytoSorbents Corporation will disclose its Q4 and full year 2024 financial results on March 6, 2025, with a conference call following the announcement. The company specializes in blood purification technologies and is advancing its innovative products like DrugSorb™-ATR to enhance surgical outcomes.
February 25, 2025 CytoSorbents Strengthens Financial Position with Successful Warrant Exercise CytoSorbents Corporation raised $1.6 million from the successful exercise of Series A Right Warrants, enhancing its liquidity and supporting ongoing innovations. CEO Dr. Phillip Chan expressed optimism for future growth as the company pursues regulatory approvals for its products.
November 07, 2024 Cytosorbents Corp Reports Q3 2024 Financial Results: A Year of Challenges and Growth Cytosorbents Corp reports a 7% revenue increase in Q3 2024, reaching $9.39 million. Despite operational challenges, the company is optimistic about future growth and innovation in blood purification technologies.
August 13, 2024 Cytosorbents Corp. Reports Q2 2024 Financial Results: An Analysis of Growth and Challenges Cytosorbents Corp. reported a 5% revenue increase in Q2 2024, driven by a surge in product sales. Despite this growth, the company faces significant challenges from inflation and operational costs, impacting its net loss. Future growth depends on product expansions and regulatory approvals.
May 09, 2024 Cytosorbents Corp. Reports Q1 2024 Financial Results: A Mixed Bag Amid Continued Challenges Cytosorbents Corp. reported $8.99 million in Q1 2024 revenue, a 14% increase year-over-year, despite facing significant operating losses and liquidity issues. The company is optimistic about recovering from COVID-19 impacts and continues to pursue financing options to improve its financial health.